Author

Laurent Peyrin-Biroulet

THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM A GLOBAL UC PATIENT SURVEY
THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM A GLOBAL UC PATIENT SURVEY

EFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIALEFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIAL
EFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIALEFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIAL

Laurent Peyrin-Biroulet  et al.

CLINICAL AND ENDOSCOPIC OUTCOMES WITH USTEKINUMAB IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE LONG-TERM EXTENSION PERIOD OF THE STARDUST TRIAL
CLINICAL AND ENDOSCOPIC OUTCOMES WITH USTEKINUMAB IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE LONG-TERM EXTENSION PERIOD OF THE STARDUST TRIAL

A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Laurent Peyrin-Biroulet  et al.

THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12
THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12

Laurent Peyrin-Biroulet  et al.

Ongoing evolution of new IBD therapies
Ongoing evolution of new IBD therapies

Laurent Peyrin-Biroulet

RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Laurent Peyrin-Biroulet  et al.

Planning for the long distance: Caring for patients with inflammatory bowel disease (Fresenius Kabi)
Planning for the long distance: Caring for patients with inflammatory bowel disease (Fresenius Kabi)

Laurent Peyrin-Biroulet  et al.

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL

FUTURE IBD: The emerging role of the IL-23 inhibitor class in Crohn’s disease (AbbVie)
FUTURE IBD: The emerging role of the IL-23 inhibitor class in Crohn’s disease (AbbVie)

Laurent Peyrin-Biroulet  et al.

Practice makes perfect: a holistic approach to remission in the clinic (Galapagos)
Practice makes perfect: a holistic approach to remission in the clinic (Galapagos)

Laurent Peyrin-Biroulet  et al.

The New Treatment Platform of Subcutaneous TNF Inhibitors in Inflammatory Bowel Disease (Celltrion Healthcare)
The New Treatment Platform of Subcutaneous TNF Inhibitors in Inflammatory Bowel Disease (Celltrion Healthcare)

Laurent Peyrin-Biroulet  et al.

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL

Laurent Peyrin-Biroulet  et al.

Breaking the ‘therapeutic ceiling’ in the management of Crohn’s disease: hype or hope? (Takeda Pharmaceuticals International AG)
Breaking the ‘therapeutic ceiling’ in the management of Crohn’s disease: hype or hope? (Takeda Pharmaceuticals International AG)

Laurent Peyrin-Biroulet  et al.

THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM A GLOBAL UC PATIENT SURVEY
THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM A GLOBAL UC PATIENT SURVEY

Laurent Peyrin-Biroulet  et al.

OZANIMOD IS AN EFFECTIVE ORAL TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS REGARDLESS OF MODERATE OR SEVERE ENDOSCOPIC DISEASE ACTIVITY: A POST HOC ANALYSIS OF TRUE NORTH
OZANIMOD IS AN EFFECTIVE ORAL TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS REGARDLESS OF MODERATE OR SEVERE ENDOSCOPIC DISEASE ACTIVITY: A POST HOC ANALYSIS OF TRUE NORTH

ASSOCIATION BETWEEN EFFICACY AND LONG-TERM OUTCOMES: FOUR YEAR RESULTS FROM THE UNIFI STUDY OF USTEKINUMAB IN ULCERATIVE COLITIS
ASSOCIATION BETWEEN EFFICACY AND LONG-TERM OUTCOMES: FOUR YEAR RESULTS FROM THE UNIFI STUDY OF USTEKINUMAB IN ULCERATIVE COLITIS

Laurent Peyrin-Biroulet  et al.

Addressing diagnostic delay and differential diagnosis
Addressing diagnostic delay and differential diagnosis

Laurent Peyrin-Biroulet

Weighing up treatment options in UC: how do we interpret the evidence for JAK inhibition? (Pfizer)
Weighing up treatment options in UC: how do we interpret the evidence for JAK inhibition? (Pfizer)

Laurent Peyrin-Biroulet  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Laurent Peyrin-Biroulet  et al.

Item 1 - 20 / 89
1
2 3 4 5